Eazi-Breed Cidr 1380 Cattle Device
Country: Netherlands
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
24-09-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
progesterone 1.38 g
Available from:
Pfizer Limited
ATC code:
QG03DA04
Pharmaceutical form:
Vaginal device
Therapeutic group:
progesterone
Therapeutic area:
Cattle
Authorization date:
2012-01-03
Summary of Product characteristics
Revised: March 2013
AN: 00091/2012
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
CIDR 1.38g
(_In AT, BE, BG, CY, CZ, EE, FI, FR, DE, EL, HU, IE, IT, LI, LT, LU, MT, NL, PL, PT, _
_RO, SL, SK, ES, UK_)
Relmont Vet
(_In DK, IS, NO and SE_)
Vaginal Delivery System for Cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE(S):
Each device contains Progesterone. 1.38 g.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Vaginal delivery system.
A “T” shape device consists of progesterone impregnated silicone elastomer skin
moulded over an inert nylon spine.
4.
CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (cows and heifers).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of the oestrous cycle in cycling cows and heifers, including:
- Synchronisation of oestrus in groups of animals.
- Synchronisation of donor and recipient animals for embryo transfer.
To be used in combination with prostaglandin F2
or analogue.
Use as recommended normally results in oestrus 48-96 hours after device removal with
the majority of animals showing oestrus within 48-72 hours.
4.3 CONTRAINDICATIONS
Do not use:
- in cows or heifers, with abnormal or immature genital tracts, or with genital infections.
- in pregnant cattle.
- within the first 35 days after calving.
4.4 SPECIAL WARNINGS
Revised: March 2013
AN: 00091/2012
Page 2 of 5
The progesterone treatment alone, according to dosage regimen proposed, is not
sufficient to induce oestrus and ovulation in all cycling females. It is advisabl
Read the complete document
